Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17754015 | 0.83 | ADRB1 (0.56) | ADRB1KCNH2MAPTALDH1A1NOTUM | |
| SCHEMBL27995386 | 0.82 | CHRNA7 (0.50) | ADRB1NOTUMNPY5RRAB9AMEN1 | |
| SCHEMBL8728925 | 0.81 | ADRB1 (0.46) | ADRB1MAPTALDH1A1HTTGPR119 | |
| SCHEMBL8054516 | 0.77 | ADRB1 (0.61) | ADRB1KCNH2MAPTALDH1A1NOTUM | |
| SCHEMBL14980549 | 0.77 | NOTUM (0.57) | ADRB1KCNH2MAPTALDH1A1NOTUM | |
| SCHEMBL19710506 | 0.77 | NPY5R (0.58) | ADRB1KCNH2MAPTALDH1A1NOTUM | |
| SCHEMBL10373770 | 0.76 | ADRB1 (0.74) | ADRB1KCNH2MAPTALDH1A1NOTUM | |
| SCHEMBL11103700 | 0.76 | ADRB1 (0.74) | ADRB1KCNH2MAPTALDH1A1NOTUM | |
| SCHEMBL23731860 | 0.76 | NOTUM (0.59) | ADRB1KCNH2MAPTALDH1A1NOTUM | |
| SCHEMBL9982790 | 0.76 | ADRB1 (0.59) | ADRB1KCNH2MAPTALDH1A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884098-B2 | 2-{[5-Fluoro-2-({3-[2-(4-morpholinyl)ethyl]phenyl}amino)-4-pyrimidinyl]amino}-N-(2-hydroxyethyl)benzamide, useful in the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884098-B2 | 2-{[5-Fluoro-2-({3-[2-(4-morpholinyl)ethyl]phenyl}amino)-4-pyrimidinyl]amino}-N-(2-hydroxyethyl)benzamide, useful in the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100016318-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016318-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-7625903-B2 | Anticancer agent; N-(1-methylethyl)-2-[(5-methyl-2-{[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)amino]benzamide | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625903-B2 | Anticancer agent; N-(1-methylethyl)-2-[(5-methyl-2-{[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)amino]benzamide | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | GLAXOSMITHKLINE LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | GLAXOSMITHKLINE LLC | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | AURKA, AURKC, AURKB | ADRB1 3287/4885KCNH2 997/4885MAPT 2387/4885 |
| US-20100016318-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | AURKA, AURKC, AURKB | ADRB1 2696/4885KCNH2 902/4885MAPT 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.